LOTTE will manufacture antibody drug substance for Ottimo Pharma’s product at LOTTE’s Syracuse Bio Campus in New York.

Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030.

Lotte Biologics signed a contract manufacturing agreement with U.K.-based biotech company Ottimo Pharma for its production of ...

Lotte Biologics Co., the biotech arm of Lotte Group, said Thursday it has signed a contract with British biotech startup ...

The Global Monoclonal Antibody Therapeutics Market is valued at approximately USD 205.09 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.0% over the forecast ...

Faster, cheaper, better protein sensing would assist scientists in searching for specific proteins in potential sources for ...

PE Hub has rounded up six deals going back to early January involving companies in the oncology segment, starting with the ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

LOTTE BIOLOGICS has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a biopharmaceutical company developing first-in-class, PD1/VEGFR2 dual pathway antibodies to ...